Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Sex Differences in Stroke Following Transcatheter Aortic Valve Replacement and the Role of Embolic Protection Devices in Women
Author(s): Mirvat Alasnag , Giulia Masiero , Chiara de Biase , et al Added: 7 months ago

CV Disease in Special Populations

Intervention
Inside the Cath Lab: Interventional AF Leaders on Stroke Prevention
Author(s): Karim Al-Azizi , Devi Nair , Added: 1 month ago
In this expert discussion, DrKarim Al-Azizi(Baylor Scott & White The Heart Hospital, US), Editor-in-Chief of the Transcatheter Academy, is joined by steering committee members DrDevi Nair(Chief VP of Research, Arkansas Heart Hospital, US) and DrMegan Coylewright(Essentia Health, US) to unpack the landmark CHAMPION-AF trial (NCT05964200) and its implications for stroke prevention in atrial… View more

Intervention

Electrophysiology & Arrhythmia
Embolic Protection and Stroke Prevention in TAVR
Author(s): Sunny Goel Added: 11 months ago
New York Valves 2025 - Dr Sunny Goel (Mount Sinai Hospital, New York, US) joins us to discuss the current devices and strategies that are used for embolic protection and stroke prevention in transcatheter aortic valve replacement (TAVR). Dr Goel highlights the lack of strong guidelines in the field and shares findings from recent studies investigating embolic protection devices.Interview… View more

Intervention
NEO-MINDSET: Aspirin Withdrawal Post-PCI Fails to Show Noninferiority for Ischaemic Events
Added: 9 months ago Source:  Radcliffe Cardiology
Early withdrawal of aspirin in favour of potent P2Y12 inhibitor monotherapy following percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) did not meet the criteria for noninferiority regarding ischaemic events compared to standard dual antiplatelet therapy (DAPT), according to the results of the NEO-MINDSET trial.¹ The strategy did, however, demonstrate superiority in… View more

Anticoagulation

Guidelines & Statements
EuroPCR 26: VESALIUS-CV: Evolocumab in Stented Patients Without Prior MI
Author(s): Brian Bergmark Added: 1 week ago
EuroPCR 2026 – Dr Brian Bergmark (Brigham and Women's Hospital, Boston, MA, US) joins us to discuss findings from the VESALIUS-CV trial, examining the effect of evolocumab in patients who have undergone coronary stenting but have no prior myocardial infarction or stroke.VESALIUS-CV is a double-blind, randomised, placebo-controlled, multicentre phase 3 trial enrolling 12,301 high-cardiovascular… View more

Intervention
TAVI Linked to Lower 1-Year Mortality and Stroke Risk Versus SAVR in Low- to Intermediate-Risk Patients
Added: 9 months ago Source:  Transcatheter Academy
A large-scale meta-analysis suggests that for patients with severe symptomatic aortic stenosis (AS) at a low- to intermediate-surgical risk, transcatheter aortic valve implantation (TAVI) is associated with a lower risk of all-cause death or any stroke at one year compared with surgical aortic valve replacement (SAVR).¹This study was an individual participant data (IPD) meta-analysis of four… View more

Demographic

Electrophysiology & Arrhythmia
Deborah Siegal
Job title: Hematologist
Dr Deborah Siegal MD MSc FRCPC is a hematologist at The Ottawa Hospital, Associate Professor of Medicine at the University of Ottawa and Scientist at the Ottawa Hospital Research Institute. She holds a Tier 2 Canada Research Chair in Anticoagulant Treatment of Cardiovascular Disease. She received MSc degrees in Pharmacology and Health Research Methodology.Her primary research areas include (i)… View more
Georgios Tsivgoulis
Prof Georgios Tsivgoulis M.D., Ph.D., MSc, FESO, FEAN is Professor of Neurology and Vice-Chairman in the Department of Neurology at the National & Kapodistrian University of Athens, School of Medicine in Greece. He is the Divisional Director of Cerebrovascular Diseases, Director of the Neurosonology Laboratory and Director of Residential Training and the Cerebrovascular Fellowship Program. He is… View more
CREST-2: Stenting Benefits Asymptomatic Carotid Stenosis
Added: 4 months ago Source:  Radcliffe Vascular
The optimal management for asymptomatic carotid stenosis has been a subject of debate, particularly with advancements in medical therapy. New findings from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) provide clarity, suggesting a benefit for carotid-artery stenting when added to intensive medical management.¹MethodologyCREST-2 involved… View more

Intervention

Prevention & Chronic Conditions
CREST-2: Stenting Benefits in Asymptomatic Carotid Stenosis
Added: 4 months ago Source:  Radcliffe Vascular
The optimal management for patients with high-grade asymptomatic carotid stenosis remains a key clinical question, particularly with advancements in medical therapy and revascularisation techniques. The CREST-2 trials were designed to assess whether adding revascularisation to intensive medical management provides a greater benefit than intensive medical management alone in this patient… View more

Guidelines & Statements

Intervention